TOKYOMEDIJAPAN MEDICAL REFERENCE
⌕ Search databaseOfficial source · PMDA / MHLW
Rx · Reference only · no online purchase

Samsca (Tolvaptan)

Samsca / Tolvaptan. Depending on strength, used for fluid retention, SIADH-related low sodium, or selected polycystic kidney disease.

PMDAproduct-level source2025-12label updated2026-10-05site verified
サムスカOD錠7.5mg/15mg/30mg・サムスカ顆粒1% · OD 7.5 mg / 15 mg / 30 mg
Japanese product photo · OD 7.5 mg / 15 mg / 30 mg · 大塚製薬
Main useDepending on strength, used for fluid retention, SIADH-related low sodium, or selected polycystic kidney disease.A brief overview of Japanese approved uses. Check the PMDA label below for product-specific conditions.
Japan product name
サムスカOD錠7.5mg/15mg/30mg・サムスカ顆粒1%
Brand
Samsca
Generic name
Tolvaptan
Japanese generic name
トルバプタン
Chinese name
托伐普坦
Marketing authorization holder
大塚製薬株式会社
Strengths
7.5 mg / 15 mg / 30 mg; granules 1%
Dosage form
OD tablet / granules
Therapeutic area
Cardiovascular
Regulatory status
Rx
Label updated
2025-12
TOKYO MEDI verified
2026-10-05
MEDICINE REFERENCE

Detailed product reference

Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.

01

Product overview

Samsca is a vasopressin-V2 antagonist producing aquaresis; Japanese formulation/strength approvals differ.

Read source section ↗
02

Mechanism of action

Blocks collecting-duct V2 signaling, reducing water reabsorption; serum sodium may rise.

Read source section ↗
03

Japanese indications & eligibility

7.5 mg/granules have broader uses; 15 mg excludes cirrhotic fluid retention; 30 mg is for SIADH/selected ADPKD.

Read source section ↗
04

Administration & dose differences

Schedules differ: heart failure often 15 mg daily, cirrhosis 7.5 mg daily; SIADH titrates sodium, ADPKD uses divided titration.

Read source section ↗
05

Adverse effects & key risks

Watch for dehydration, hypernatremia, rapid sodium correction and liver injury.

Read source section ↗
06

Contraindications & special populations

Contraindications include impaired thirst/fluid intake and pregnancy, with additional indication-specific renal/liver/sodium restrictions.

Read source section ↗
07

Drug interactions

Review CYP3A modifiers, grapefruit juice, diuretics and antihypertensives. Follow the clinical fluid plan.

Read source section ↗
08

Assessment & monitoring

Monitor sodium, fluid balance, weight, urine output and indication-specific liver function.

Read source section ↗
09

Storage & handling

Store at room temperature; protect OD tablets from moisture after opening the aluminum pouch.

Read source section ↗
10

Sources & verification

Product checked ·

Official source

These links go directly to PMDA records for this Japanese product. Professional and patient-facing sources are separated.